dr. jason luke on sequencing targeted and immunotherapy agents in braf melanoma
Published 7 years ago • 89 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
8:49
sequencing of checkpoint agents in melanoma
-
1:42
dr. jason luke describes results from the phase iii combi-d trial
-
1:30
dr. jason luke discusses nivolumab and pembrolizumab in melanoma
-
1:09
dr. jason luke talks about advances in how melanoma is diagnosed
-
1:06
jason luke, md: the impact of braf/mek inhibitors in melanoma
-
1:20
dr. luke on immunotherapy advancements in melanoma
-
9:43
sequencing dual braf-mek inhibition and immunotherapy
-
1:10
dr. luke on ongoing studies with immunotherapy in melanoma
-
4:33
melanoma - overview (signs and symptoms, pathology, risk factors, treatment)
-
38:01
melanoma immunotherapy with dr. jedd wolchok
-
8:35
long-term results for immunotherapy in melanoma
-
1:51
dr. luke on immunotherapy diagnostics in melanoma
-
0:59
dr. luke on treatment options in metastatic melanoma
-
6:12
braf as a driver in melanoma
-
5:30
sequencing and timing: unanswered questions in melanoma
-
2:05
dr. luke on challenges with immunotherapy in melanoma
-
1:28
dr. puzanov on sequencing targeted therapy and immunotherapy in melanoma
-
9:07
optimal treatment of metastatic melanoma at progression
-
6:39
questions about sequencing in braf-mutant melanoma
-
1:48
dr. luke on current and emerging treatment approaches in metastatic melanoma
-
8:04
treatment sequencing in braf metastatic melanoma
-
1:06
dr. luke on the future role of immunotherapy combinations in melanoma